Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x100px
Organisation › Details

Biocius Life Sciences Inc.

Biotrove announced today that it is forming a wholly owned subsidiary named BIOCIUS Life Sciences to hold the assets of the RapidFire Business Unit. Upon completion of Life Technologies proposed acquisition of BioTrove, also announced today, BIOCIUS Life Sciences will be spun-out as an independent operating company. The current BioTrove investors will continue to support the BIOCIUS subsidiary and proposed eventual spin-out. Led by Chairman and Chief Executive Officer Jeffrey Leathe, Rapid Fire's experienced team of innovative scientists and engineers will also remain intact. According to Mr. Leathe, "Effective at the closing of the proposed sale of Biotrove to Life Technologies, BIOCIUS, through the RapidFire brand, will intensify its focus on pioneering new efforts toward eliminating bottlenecks in the drug discovery pipeline. We plan to expand our portfolio of products and service capabilities--creating additional value for our many pharma and biotech customers. BIOCIUS has a strong pipeline of products and services and will be well capitalized and positioned in the marketplace to continue as a technology leader in drug discovery solutions." The RapidFire business unit is comprised of solid, propriety technologies and the proposed formation of BIOCIUS is a logical, strategic step to foster rapid growth. RapidFire almost doubled its 2008 sales, successfully launching the RF 300 system for in vitro ADME; expanding geographically by installing several systems across Europe and Canada, and by entering a distribution arrangement in Asia. "This is a wonderful opportunity for the RapidFire team to focus on our clients, scientific collaborations and business goals," said Dr. Can 'Jon' Özbal, BIOCIUS Chief Operating Officer and former Vice President of the RapidFire Business Unit. "We can now exclusively drive the high-throughput screening portfolio and concentrate on our application areas of Lead Discovery and in vitro ADME. The entire team that has been the dynamic force behind the RapidFire brand will move to BIOCIUS, ensuring a smooth transition for our clients and business partners." Named from the Greek word "BIO" (life) and the Latin word "OCIUS" (faster), BIOCIUS Life Sciences, a wholly owned subsidiary of BioTrove, Inc. provides the biopharmaceutical industry with faster answers: Products and services committed to speed and accuracy to help exceed business goals. The RapidFire system feeds samples directly to the mass spectrometer, requiring no labels or surrogates, helping to eliminate the bottleneck of samples that require screening in the drug discovery process. RapidFire Mass Spectrometry is routinely used in many applications including the high-throughput screening of previously intractable drug targets and in vitro ADME assays. *


Period Start 2009-11-10 splitoff announced
  Predecessor BioTrove Inc.
Products Industry RapidFire™ Mass Spectrometry system
  Industry 2 RapidFire™ Lead Discovery (service)
Region Region Wakefield, MA
  Country United States (USA)
  Street 11 Audubon Road
  City 01880 Wakefield, MA
  Tel +1-718-928-2700
    Address record changed: 2020-12-02
Basic data Employees B: 11 to 50 (2011-03-01)
    * Document for »About Section«: 
Record changed: 2023-07-10


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Agilent (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top